These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37452557)

  • 1. Editorial Comment to Efficacy and safety of pembrolizumab and axitinib as first-line treatment for patients with advanced renal cell carcinoma: Real-world experience in Japan.
    Kondo T
    Int J Urol; 2023 Sep; 30(9):777-778. PubMed ID: 37452557
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial Comment from Dr Miyake to Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART).
    Miyake M
    Int J Urol; 2024 Mar; 31(3):273. PubMed ID: 38173077
    [No Abstract]   [Full Text] [Related]  

  • 3. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
    Powles T; Plimack ER; Soulières D; Waddell T; Stus V; Gafanov R; Nosov D; Pouliot F; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Bedke J; Tamada S; Yin L; Chen M; Molife LR; Atkins MB; Rini BI
    Lancet Oncol; 2020 Dec; 21(12):1563-1573. PubMed ID: 33284113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of pembrolizumab and axitinib as first-line treatment for patients with advanced renal cell carcinoma: Real-world experience in Japan.
    Harada KI; Sato R; Bando Y; Sano A; Matsushita Y; Tamura K; Terakawa T; Furukawa J; Fujimoto N; Fujisawa M; Miyake H
    Int J Urol; 2023 Sep; 30(9):772-777. PubMed ID: 37345413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [First-line therapy in advanced renal cell carcinoma : A randomized, open-label phase III study evaluating the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib compared to sunitinib monotherapy as first-line treatment for locally advanced or metastatic renal cell carcinoma (mRCC) (Keynote-426) - AN 39/16 of the AUO].
    Rexer H; Bedke J
    Urologe A; 2017 Mar; 56(3):385-386. PubMed ID: 28246756
    [No Abstract]   [Full Text] [Related]  

  • 6. Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial.
    Atkins MB; Plimack ER; Puzanov I; Fishman MN; McDermott DF; Cho DC; Vaishampayan U; George S; Tarazi JC; Duggan W; Perini R; Thakur M; Fernandez KC; Choueiri TK
    Eur J Cancer; 2021 Mar; 145():1-10. PubMed ID: 33412465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
    Rini BI; Plimack ER; Stus V; Gafanov R; Hawkins R; Nosov D; Pouliot F; Alekseev B; Soulières D; Melichar B; Vynnychenko I; Kryzhanivska A; Bondarenko I; Azevedo SJ; Borchiellini D; Szczylik C; Markus M; McDermott RS; Bedke J; Tartas S; Chang YH; Tamada S; Shou Q; Perini RF; Chen M; Atkins MB; Powles T;
    N Engl J Med; 2019 Mar; 380(12):1116-1127. PubMed ID: 30779529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
    Choueiri TK; Larkin J; Oya M; Thistlethwaite F; Martignoni M; Nathan P; Powles T; McDermott D; Robbins PB; Chism DD; Cho D; Atkins MB; Gordon MS; Gupta S; Uemura H; Tomita Y; Compagnoni A; Fowst C; di Pietro A; Rini BI
    Lancet Oncol; 2018 Apr; 19(4):451-460. PubMed ID: 29530667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Life-threatening Hyperkalemia Associated with Axitinib Treatment in Patients with Recurrent Renal Carcinoma.
    Godo S; Yoshida Y; Kawamorita N; Mitsuzuka K; Kawazoe Y; Fujita M; Kudo D; Nomura R; Shimokawa H; Kushimoto S
    Intern Med; 2018 Oct; 57(19):2895-2900. PubMed ID: 29780111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
    Watson TR; Gao X; Reynolds KL; Kong CY
    JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma.
    Spisarová M; Melichar B; Vitásková D; Študentová H
    Expert Rev Anticancer Ther; 2021 Jul; 21(7):693-703. PubMed ID: 33794744
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma in the U.S.
    Ding D; Hu H; Shi Y; She L; Yao L; Zhu Y; Zeng S; Shen L; Huang J
    Oncologist; 2021 Feb; 26(2):e290-e297. PubMed ID: 32918790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma.
    Bensimon AG; Zhong Y; Swami U; Briggs A; Young J; Feng Y; Song Y; Signorovitch J; Adejoro O; Chakravarty A; Chen M; Perini RF; Geynisman DM
    Curr Med Res Opin; 2020 Sep; 36(9):1507-1517. PubMed ID: 32697113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicity Management of Front-Line Pembrolizumab Combined With Axitinib in Clear Cell Metastatic Renal Cell Carcinoma: A Case Study Approach.
    Wood LS; Ornstein MC
    JCO Oncol Pract; 2020 Feb; 16(2_suppl):15s-19s. PubMed ID: 32045538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of Neoadjuvant Axitinib Influenced the Efficacy in Patients With Advanced Renal Cell Carcinoma.
    Yamamoto Y; Otori T; Inoue R; Yano S; Hirata H; Matsumoto H; Matsuyama K; Matsuyama H
    J Clin Pharmacol; 2020 Feb; 60(2):256-263. PubMed ID: 31538342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of pembrolizumab plus axitinib as first-line therapy for advanced renal cell carcinoma.
    Zhu J; Zhang T; Wan N; Liang Z; Li J; Chen X; Liang W; Jiang J
    Immunotherapy; 2020 Dec; 12(17):1237-1246. PubMed ID: 32878521
    [No Abstract]   [Full Text] [Related]  

  • 17. Assessment of Efficacy, Safety, and Quality of Life of 124 Patients Treated With Axitinib as Second-Line Therapy for Metastatic Renal-Cell Carcinoma: Experience in Real-World Clinical Practice in Japan.
    Miyake H; Harada KI; Ozono S; Fujisawa M
    Clin Genitourin Cancer; 2017 Feb; 15(1):122-128. PubMed ID: 27473522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.
    Heo JH; Park C; Ghosh S; Park SK; Zivkovic M; Rascati KL
    J Clin Pharm Ther; 2021 Feb; 46(1):35-49. PubMed ID: 33112003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan.
    Koie T; Ohyama C; Yoneyama T; Yamamoto H; Imai A; Hatakeyama S; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
    BMC Urol; 2015 Apr; 15():32. PubMed ID: 25887125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sinus Bradycardia With Pauses Owing to Axitinib/Pembrolizumab in a Metastatic Renal Cell Carcinoma Patient.
    McGreevy JW; Ghous G; Shoukat HMH; Zafar MU; Tarar ZI
    Am J Ther; 2023 May; 30(3):e304-e305. PubMed ID: 37278713
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.